SecBot SecBot
Biotech Drug Report Generated Oct 25, 2026

SCY-770

SCYX·Scynexis
NEUTRAL
Drug Impact Rating6/10
Trial phase
Phase 1 completed; Phase 2 ready
Time to market
Minimum 3-4 years, assuming positive Phase 2 data drives Phase 3 and potential accelerated approval via FDA-recognized surrogate endpoint (total kidney volume)
Why 6/10
The next hard, dated catalyst for SCY-770 is the Phase 2 proof-of-concept early efficacy readout expected in H2 2027 (~8-14 months out). The Phase 2 study initiation (imminent, Q4 2026) is an operational milestone, not a binary catalyst. SCY-770 is a major value driver but SCYX also has SCY-247 (antifungal with BARDA funding) and BREXAFEMME licensing revenue, so the company is not a single-asset binary.
Actionable Insight NEUTRAL

Watch for the Phase 2 proof-of-concept study initiation in Q4 2026 (imminent) and, more importantly, the early efficacy readout on total kidney volume expected in the second half of 2027. SCY-770 must demonstrate a meaningful reduction in kidney growth versus placebo to justify the valuation implied by analyst targets (~$36 mean). Until then, the stock is driven by SCY-247 antifungal progress and the $214M BARDA contract, SCY-770 remains a high-risk/high-reward pipeline component.

Price Chart

Loading chart...

Executive Summary

SCY-770 is a first-in-class oral direct AMPK activator being developed by SCYNEXIS (NASDAQ: SCYX) for Autosomal Dominant Polycystic Kidney Disease (ADPKD), a rare genetic kidney disorder. Acquired from Poxel in March 2026 for $8M upfront (up to $196M total), the drug completed a positive Phase 1 study in October 2026 showing favorable safety/tolerability at higher doses in 25 healthy volunteers. A Phase 2 proof-of-concept study is expected to launch in Q4 2026 with an early efficacy readout in H2 2027. SCY-770 has FDA Orphan Drug Designation and targets a market where the only approved disease-modifying therapy is Tolvaptan (Jynarque). The drug represents a major pipeline expansion for SCYX beyond its antifungal platform, but remains early-stage with no efficacy data in patients yet.

How It Works

SCY-770 activates AMPK, a protein that acts as the cell's energy master switch. In ADPKD, abnormal cell growth causes fluid-filled cysts to form and enlarge in the kidneys. By turning on AMPK, SCY-770 aims to normalize cell energy use and suppress the signals driving cyst growth, potentially slowing or halting disease progression. It is taken orally as a pill.

Trial Status

Phase 1 completed October 2026: 25 healthy participants dosed at 500mg single dose (fed/fasted), 750mg once daily x7 days, or 500mg twice daily x7 days vs placebo. Well tolerated with favorable safety profile at all doses. Phase 2 proof-of-concept study in ADPKD patients expected to initiate in Q4 2026, with early efficacy readout anticipated H2 2027.

The Two-Sided Case

▲ Bull Case5
First-in-class mechanism targeting root cause of ADPKD with no disease-modifying oral options beyond Tolvaptan (Jynarque), which has tolerability issues
FDA Orphan Drug Designation provides 7-year market exclusivity, regulatory fee waivers, and potential accelerated approval via total kidney volume surrogate endpoint
Phase 1 showed clean safety at doses higher than previously tested, 273 subjects dosed across 8 trials with prior PXL770 studies, supporting the dose range for Phase 2
ADPKD market projected to reach ~$3.8B; a safe, effective oral alternative to Tolvaptan could capture meaningful share
Strong analyst conviction, 3 Strong Buy, 5 Buy ratings with mean price target ~$36.33 (860% upside from ~$3.79) and Guggenheim maintaining Buy as recently as August 2026
▼ Bear Case5
SCY-770 has ZERO efficacy data in ADPKD patients, the prior PXL770 Phase 2a in NASH (a different disease) missed its primary endpoint on liver fat reduction
Phase 2 is still a proof-of-concept study; the early efficacy readout (H2 2027) is binary and could fail to show meaningful total kidney volume reduction
Tolvaptan (Jynarque, Otsuka) is already approved and established with a large treated population; competitive entrant needs to demonstrate superiority or better tolerability
SCYX has a small cash position of $71.1M (Q2 2026); the $8M upfront + milestone structure of the Poxel acquisition plus Phase 2 costs may require future dilutive financing even with runway into 2029
Stock trades near 52-week lows ($3.53-$9.12 range), reflecting market skepticism about execution risk and the long timeline to potential revenue

Upcoming Catalysts

  • Phase 2 proof-of-concept study initiation (imminent, Q4 2026)
  • Early efficacy readout from Phase 2 (H2 2027)
  • Q3 2026 earnings report (November 11, 2026)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Scynexis Press Release SCYX ·Originating report

Sources · 6

Hover a chip for the title
1 ir.scynexis.com2 ir.scynexis.com3 poxelpharma.com4 scynexis.com5 ir.scynexis.com6 biospace.com